Oncology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Erbitux in addition to chemotherapy for colorectal cancer with inoperable metastatic liver lesions can improve tumor shrinkage

Adding Cetuximab ( Erbitux ) to neoadjuvant chemotherapy can shrink tumours leading to increased potentially curative surgery in patients who have colorectal cancer with inoperable metastatic liver lesions.

Over half of all patients with colorectal cancer develop metastatic disease, most commonly in the liver. Surgical removal of colorectal liver metastases is potentially curative, but about 80% of patients with colorectal liver metastases have inoperable disease and poor prognosis at presentation. However, previous research suggests that neoadjuvant treatment with Irinotecan or Oxaliplatin-based chemotherapy can shrink tumours and consequently make surgery viable.

Most colorectal cancers express epidermal growth factor receptor ( EGFR ), high levels of which are linked to more metastases and poorer outcome. Cetuximab is a monoclonal antibody that targets and disables EGFR and has been shown to prevent cancer cell growth, and might increase the effectiveness of chemotherapy in patients with colorectal liver metastases.

Gunnar Folprecht, from University Hospital Carl Gustav Carus, Dresden, Germany, and colleagues did the CELIM randomised trial to examine the effectiveness of adding Cetuximab to neoadjuvant chemotherapy to improve tumour response and maximise rates of potentially curable surgery in patients with colorectal liver metastases.

109 patients were randomly assigned to treatment with Cetuximab plus FOLFOX6 ( Oxaliplatin, Fluorouracil, and Folinic acid, group A ) or Cetuximab plus FOLFIRI ( Irinotecan, Fluorouracil, and Folinic acid, group B ). Tumour response and suitability for surgery were assessed every 4 cycles ( 8 weeks ) using CT or MRI. Patients with resectable disease after assessment were offered liver surgery.
The Authors also did a blinded surgical review of MRI and CT scans to provide an objective assessment of how suitability for surgery changed during treatment.

Findings showed that treatment with Cetuximab resulted in high tumour response rates and a significant increase ( 28% ) in the proportion of tumours that were amenable to surgery compared with at the start of the study.

Partial or complete tumour response was shown in 68% of patients in group A and 57% of patients in group B. Tumour response was higher in patients with KRAS wild-type tumours ( 70% ) compared with patients with KRAS tumour mutations ( 41% ), consistent with results of previous studies which have shown that this mutation confers resistance to Cetuximab.

Overall, surgery was achieved in 36 of 106 patients ( 34% ). Importantly, the blinded review found that treatment with Cetuximab significantly increased the proportion of tumours that were amenable to surgery, with 60% ( 41 of 68 patients ) of tumours judged to be resectable after treatment compared with 32% ( 22 of 68 patients ) at the start of the study.

The treatment was generally well tolerated. Grade 3 toxicity occurred in 72% of patients, the most common toxicities being skin reactions and neutropenia. ( Xagena )

Source: Lancet Oncology, 2009